Celecoxib News and Research

RSS

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004

Following the withdrawal of Vioxx, the European Medicines Agency has been asked to review of COX-2 inhibitor medicines

Following the worldwide withdrawal of Vioxx (rofecoxib), the European Medicines Agency (EMEA) has been asked by the European Commission, as a precautionary measure, to conduct a review of COX-2 inhibitor medicines.

25 Oct 2004

COX-2 agents have influenced the way physicians prescribe rheumatology medication

COX-2 agents, with their perceived reduction in side effects, have contributed substantially to a dramatic increase in NSAIDs (non-steroidal anti-inflammatory drugs) prescription utilization and influenced the way physicians prescribe rheumatology medication

18 Oct 2004

Canadian Rheumatology Association issues statement on Vioxx alternatives

The Canadian Rheumatology Association (CRA) has issued a statement to its 350 members and other interested parties, recommending alternative treatment considerations in the wake of the worldwide recall of Merck's rofecoxib, (Vioxx(R)) last week.

7 Oct 2004

EMEA statement following withdrawal of Vioxx (rofecoxib)

EU regulators met with the marketing authorisation holder of Vioxx (rofecoxib), Merck Sharp & Dohme, on 4-5 October 2004 at the informal meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) held in Scheveningen, The Netherlands.

6 Oct 2004

Data demonstrate that Celebrex does not increase the risk of heart attack or stroke in patients with arthritis and pain

Pfizer has said that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to completion.

4 Oct 2004

Evidence that new anti-inflammatory drug may sensitize leukemia, and breast and lung cancers to conventional chemotherapy

Ohio researchers have used a recently developed anti-inflammatory drug as a starting point to construct a possible new, targeted anti-cancer agent.

10 Jul 2004

Prescription pain medications may slow healing process in shoulder operations

A study of small laboratory animals suggests that prescription pain medications may delay healing in rotator cuff repair, a common shoulder operation, according to a new study by a team of doctors at the Hospital for Special Surgery.

26 Jun 2004

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

Women who regularly take aspirin at lower risk of breast cancer

Women who regularly take aspirin seem to be at lower risk of the most common type of breast cancer than those who do not take aspirin, report researchers from Columbia University's Mailman School of Public Health and College of Physicians & Surgeons, Weill Cornell Medical College , and New York-Presbyterian Hospital.

31 May 2004

Proteomics helps fight colon cancer

Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis.

19 Apr 2004